Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H27N3.2ClH |
Molecular Weight | 394.381 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.C[C@H]1CN(CCCN2C3=C(C=CC=C3)C4=C2C=CC=C4)C[C@@H](C)N1
InChI
InChIKey=ZWHRZGHGYMUSRM-VWDRLOGHSA-N
InChI=1S/C21H27N3.2ClH/c1-16-14-23(15-17(2)22-16)12-7-13-24-20-10-5-3-8-18(20)19-9-4-6-11-21(19)24;;/h3-6,8-11,16-17,22H,7,12-15H2,1-2H3;2*1H/t16-,17+;;
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C21H27N3 |
Molecular Weight | 321.4592 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Rimcazole is a carbazole derivative that acts as a sigma receptor antagonist and studied as potential antipsychotic agent for the treatment of acute schizophrenic patients. In open-clinical trials Rimcazole (BW 234U) appears to be effective in acute schizophrenic patients. However, subsequent clinical trials demonstrated that rimcazole lacked efficacy in schizophrenic patients and it is now primarily used as an experimental tool. In addition to its actions as receptor antagonist, rimcazole also has high affinity for dopamine transporters, and inrecent years it has served as a lead compound for the development of novel dopamine transporter ligands.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2873494 |
|||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435903 |
PubMed
Title | Date | PubMed |
---|---|---|
Neuropharmacological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity. | 1996 Nov 21 |
|
Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole): irreversible ligands for the dopamine transporter. | 1997 Dec 19 |
|
Effect of sigma ligands on the cocaine-induced convulsions in mice. | 1999 Nov-Dec |
|
Review of the pharmacological and clinical profile of rimcazole. | 2004 Spring |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9826105
5 mg/kg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:05:10 GMT 2023
by
admin
on
Fri Dec 15 15:05:10 GMT 2023
|
Record UNII |
2XAC11FCQ4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 15:05:10 GMT 2023 , Edited by admin on Fri Dec 15 15:05:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C152219
Created by
admin on Fri Dec 15 15:05:10 GMT 2023 , Edited by admin on Fri Dec 15 15:05:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL275707
Created by
admin on Fri Dec 15 15:05:10 GMT 2023 , Edited by admin on Fri Dec 15 15:05:10 GMT 2023
|
PRIMARY | |||
|
75859-03-9
Created by
admin on Fri Dec 15 15:05:10 GMT 2023 , Edited by admin on Fri Dec 15 15:05:10 GMT 2023
|
PRIMARY | |||
|
53388
Created by
admin on Fri Dec 15 15:05:10 GMT 2023 , Edited by admin on Fri Dec 15 15:05:10 GMT 2023
|
PRIMARY | |||
|
T-46
Created by
admin on Fri Dec 15 15:05:10 GMT 2023 , Edited by admin on Fri Dec 15 15:05:10 GMT 2023
|
PRIMARY | |||
|
2XAC11FCQ4
Created by
admin on Fri Dec 15 15:05:10 GMT 2023 , Edited by admin on Fri Dec 15 15:05:10 GMT 2023
|
PRIMARY | |||
|
DTXSID2048161
Created by
admin on Fri Dec 15 15:05:10 GMT 2023 , Edited by admin on Fri Dec 15 15:05:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |